Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Enzo Biochem management to meet virtually with BTIG » 08:04
06/01/20
06/01
08:04
06/01/20
08:04
ENZ

Enzo Biochem

$2.84 /

-0.02 (-0.70%)

Virtual Meetings to be…

Virtual Meetings to be held June 3-4 hosted by BTIG.

ShowHide Related Items >><<
ENZ Enzo Biochem
$2.84 /

-0.02 (-0.70%)

ENZ Enzo Biochem
$2.84 /

-0.02 (-0.70%)

Over a week ago
Hot Stocks
Enzo Biochem launches test for detection of SARS-CoV-2 IgG antibody » 08:13
05/20/20
05/20
08:13
05/20/20
08:13
ENZ

Enzo Biochem

$2.97 /

+0.055 (+1.89%)

Enzo Biochem announced…

Enzo Biochem announced that it is currently offering a SARS-CoV-2 IgG ELISA assay kit for serological detection of IgG antibodies against the novel coronavirus under the FDA's Emergency Use Authorization authority as both products and services. While molecular tests detect the presence of viral RNA to diagnose active infection, serological tests are used to detect the presence of antibodies to the SARS-CoV-2 virus. The emphasis in the coming months is shifting towards mass-market serological testing to determine if individuals were previously exposed to the novel coronavirus and are likely to have already recovered from infection. Accordingly, it is believed that serological testing will play an important role in enabling the workforce to return to their places of employment. The assay permits the qualitative detection of IgG antibodies to SARS-CoV-2 in human serum and is designed to provide accurate results in a clinical laboratory setting with low- to high-throughput processing of specimens. In a clinical study, performance of the SARS-CoV-2 ELISA Kit was compared with a molecular diagnosis using serum samples from approximately 150 individuals. Positive percent agreement and negative percent agreement with a comparator PCR observed 96.5% specificity and 100% sensitivity. Clinical assays for antibodies must be reliable and have high specificity without cross-reactivity to related viruses. These new serological tests, which are built on Enzo's proprietary ELISA platform, work with serum specimens and are formatted for both manual test processing situations as well as automated, high-throughput clinical workflows. Enzyme-linked immunosorbent assay is an analytical, plate-based technique to detect the presence of a target analyte in a liquid sample using affinity reagents. The Immunoglobulin G Antibody Kit detects IgG antibodies specific for SARS-CoV-2 to identify individuals previously exposed to and infected by the coronavirus, even if they have never displayed symptoms. Enzo's high-throughput kit for IgG antibody utilizes a routine blood collection at a lab's patient service center, a doctor's office, or a hospital. The sample is then sent to the clinical laboratory for processing and analysis. This workflow permits scalable testing to be performed under controlled conditions to deliver accurate and sensitive results. Enzo's proprietary 96-well ELISA based technology is readily scalable to meet the needs of the clinical laboratory environment, while providing reliable and economical results. All kits are manufactured at Enzo's GMP certified production facilities.

ShowHide Related Items >><<
ENZ Enzo Biochem
$2.97 /

+0.055 (+1.89%)

ENZ Enzo Biochem
$2.97 /

+0.055 (+1.89%)

Hot Stocks
Enzo Biochem issued U.S. patent for methods of producing monoclonal antibodies » 08:36
05/12/20
05/12
08:36
05/12/20
08:36
ENZ

Enzo Biochem

$2.80 /

+ (+0.00%)

Enzo Biochem announced…

Enzo Biochem announced the recent issuance of U.S. Patent No. 10,626,170 entitled Sulfonated Sclerostin, Antibodies, Epitopes and Methods for Identification and Use Therefor. The patent is directed to methods for producing monoclonal antibodies against specific regions of human Sclerostin, a protein that is a negative regulator of bone growth. Inhibition of Sclerostin using monoclonal antibodies can be used to promote bone growth for the treatment of osteoporosis. U.S. Patent No. 10,626,170 is a member of a broader U.S. and international patent family that includes issued patents and pending patent applications directed to antibodies and their use in inhibiting Sclerostin as well as small synthetic peptides and their use in inhibiting Sclerostin in the treatment of bone disorders such as osteoporosis.

ShowHide Related Items >><<
ENZ Enzo Biochem
$2.80 /

+ (+0.00%)

ENZ Enzo Biochem
$2.80 /

+ (+0.00%)

Over a month ago
Hot Stocks
Enzo Biochem issued U.S. patent for methods of using SK1-I » 08:06
04/29/20
04/29
08:06
04/29/20
08:06
ENZ

Enzo Biochem

$3.23 /

+0.52 (+19.19%)

Enzo Biochem announced…

Enzo Biochem announced the recent issuance of U.S. Patent No. 10,624,863 entitled Sphingosine Kinase Type 1 Inhibitors and Uses Thereof. The patent is directed to methods for inhibiting the enzyme Sphingosine kinase 1 in patients using the company's proprietary compound SK1-I and related Sphingosine kinase 1 inhibitors. In February, Enzo reported the publication of work by academic researchers demonstrating that drug candidate SK1-I decreased Interferon signature, pDC activation and glomerulonephritis, the inflammation of the filtration units of the kidney, in a chemically induced mouse model of lupus. In more detail, that work demonstrated that SK1-I reduced the levels of inflammatory cytokines including Interleukin-6, Tumor Necrosis Factor alpha, and Interferon-alpha and -beta in the animal model. Significantly, elevated levels of inflammatory cytokines, particularly IL-6, are reported to be associated with the development of respiratory failure in COVID-19 patients. Based on the results obtained in the lupus model and prior work demonstrating the anti-inflammatory activity of SK1-I in animal models of other immune disorders and on isolated human blood cells, the company is exploring avenues for the development of SK1-I as a potential treatment for COVID-19. Sphingosine kinase 1 is a key enzyme in the Sphingosine cell-signaling pathway that has been implicated in tumor cell growth and pathological inflammation. The enzyme acts by phosphorylating the cellular lipid Sphingosine to form Sphingosine 1-Phosphate, an important biological mediator of cell proliferation and immune function. SK1-I is a small molecule that specifically inhibits Sphingosine kinase 1. U.S. Patent No. 10,624,863 is the latest member of a family of issued U.S. patents, co-owned by Enzo and Virginia Commonwealth University and exclusively licensed by VCU to Enzo, that cover SK1-I and related compounds and their use in the treatment of various cancers and immune-inflammatory disorders. Foreign patent family members have also issued or been allowed.

Hot Stocks
Enzo Biochem launches proprietary COVID-19 test under FDA EUA » 08:03
04/23/20
04/23
08:03
04/23/20
08:03
ENZ

Enzo Biochem

$2.17 /

-0.01 (-0.46%)

Enzo Biochem announced…

Enzo Biochem announced its Comprehensive COVID-19 Program incorporating its molecular diagnostic virus screening products, detection for immunity through IgG/IgM serological ELISA products, detection of inflammation on Enzo's ELISA platform, and a promising proprietary drug candidate, or SK1-I. Enzo is utilizing its technological and research and development capabilities, manufacturing infrastructure strength and clinical diagnostic capabilities to provide products that address gaps in performance, cost, supply obtainability and safety. Most diagnostic platforms offered by others are 'closed' systems and have no flexibility with regards to adoptability for other infectious agents, have limited supplier relationships, and have no direct connection with the patient or the event. These underlying problems have manifested themselves in the current COVID-19 crisis. Enzo's Comprehensive COVID-19 Program showcases Enzo's ability to respond to the current challenges plaguing the healthcare market. Enzo's Diagnostics division is currently offering next-generation COVID-19 test kits under the FDA's Emergency Use Authorization, or EUA, authority. The tests, which use Enzo's proprietary GENFLEX open diagnostic platform, include a collection system, sample processing and molecular analytic products that address and circumvent the supply shortfalls throughout the diagnostic market.

Hot Stocks
Enzo Clinical Labs launches drive-through COVID-19 test facility on Long Island » 07:39
03/24/20
03/24
07:39
03/24/20
07:39
ENZ

Enzo Biochem

$2.28 /

-0.5 (-17.99%)

Enzo Biochem announced…

Enzo Biochem announced its wholly owned subsidiary, Enzo Clinical Labs, Inc., has expanded its screening services for COVID-19. Following the company's March 6 announcement regarding the initiation of accepting specimens for novel Coronavirus (COVID-19) testing, Enzo is now directly collecting specimens at a drive-through facility by appointment in Enzo's laboratory complex in Farmingdale, New York. This facility has been set up with support from local and state officials. As one of the first independent drive-through testing facilities on Long Island, NY, it is easily accessible for Nassau and Suffolk County residents and is now in operation. The goal of this testing site is to help the local community improve virus surveillance and reduce pressure on the regional hospital systems.

Hot Stocks
Enzo Biochem rises 50.2% » 12:00
03/06/20
03/06
12:00
03/06/20
12:00
ENZ

Enzo Biochem

$3.40 /

+1.155 (+51.45%)

Enzo Biochem is up 50.2%,…

Enzo Biochem is up 50.2%, or $1.13 to $3.39.

ShowHide Related Items >><<
Hot Stocks
Enzo Biochem rises 38.5% » 10:00
03/06/20
03/06
10:00
03/06/20
10:00
ENZ

Enzo Biochem

$3.12 /

+0.875 (+38.98%)

Enzo Biochem is up 38.5%,…

Enzo Biochem is up 38.5%, or 87c to $3.13.

ShowHide Related Items >><<
Hot Stocks
Enzo Biochem rises 47.8% » 09:47
03/06/20
03/06
09:47
03/06/20
09:47
ENZ

Enzo Biochem

$3.30 /

+1.055 (+46.99%)

Enzo Biochem is up 47.8%,…

Enzo Biochem is up 47.8%, or $1.08 to $3.34.

ShowHide Related Items >><<
Hot Stocks
Enzo Clinical Labs to begin accepting specimens for COVID-19 testing next week » 08:06
03/06/20
03/06
08:06
03/06/20
08:06
ENZ

Enzo Biochem

$2.25 /

-0.005 (-0.22%)

Enzo Biochem announced…

Enzo Biochem announced that its wholly owned subsidiary, Enzo Clinical Labs, will begin accepting specimens for novel Coronavirus (COVID-19) testing next week. COVID-19 is a contagious virus that is believed to spread by person-to-person transmission and may have serious health consequences. The virus has infected more than 93,000 people globally including recent detections in the United States. Enzo has many years of experience processing specimens for the detection of viral pathogens. The test used by Enzo is a molecular test that determines the presence of viral RNA in respiratory specimens collected from patients by healthcare providers.

ShowHide Related Items >><<

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.